Striatech celebrates its 5th anniversary with a top-class Symposium on the topic of translating visual restoration from mouse to human. Presentations will be given by Professor Eberhart Zrenner (University of Tübingen), Professor Constance Cepko (Harvard Medical School) and Miikka Terho (Pioneer Retina Implant Patient, Finland). In addition, the speakers will highlight important aspects and directions in this area of research in a moderated panel discussion.
This Journal Club provides insights into mechanisms that promote retinal ganglion cell (RGC) axon regeneration in vertebrates after optic nerve injury.
Meet us at the 2023 ARVO Meeting in New Orleans, La. and see our OptoDrum, Photorefractor and Keratometer in action! April 23 – 27
T.J. Hollingsworth presents his work where he characterized a new polygenic mouse model of inherited retinal dystrophies, the BXD32 mouse strain. He presents evidence that a proinflammatory environment in the retina supports and accelerates the degeneration of the retina and the loss of visual function.
Peroxisomal disorders and the PEX1-G844D mouse model for mild Zellweger Spectrum Disorder (ZSD), leads to retinal degeneration and vision loss. Catherine Argyriou will describe how her team used AAV8-mediated gene delivery to robustly and durably improve functional vision, retinal response, retinal structure, and biochemical metabolites in ZSD-mice.
This presentation will outline the pathobiology and visual phenotype of immune mediated optic neuropathies that include Multiple Sclerosis (MS), Neuromylitis optica spectrum disorders (NMOSD), and Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Meet us at the 18th International Myopia Conference (IMC) in Rotterdam and see our Photorefractor and Keratometer!
In retinal vein occlusion (RVO), non-apoptotic expression of endothelial caspase-9 (EC Casp9) induces pathology including retinal edema, capillary ischemia, and neurodegeneration. Crystal Colón Ortiz presents mechanistic insights into EC Casp9 action, and the behavioral consequences such as contrast sensitivity decline.
Find us at booth #2523 in Denver! After more than 3 years, we cannot wait to connect with you in-person again.
Jana Remlinger et al. showed preserved visual function and ameliorated course of disease after anti-FcRn treatment in an experimental model using a monoclonal MOG-IgG to mimic MOGAD.
